期刊文献+

6-氟-4-(N-芳基)胺基喹唑啉类化合物的微波合成及生物活性研究 被引量:8

Synthesis and Bioactivity of 6-Fluoro-4-(N-aryl)aminoquinazoline Compounds under Microwave Irradiation
在线阅读 下载PDF
导出
摘要 经2-氨基-5-氟苯甲酸与甲酰胺闭环、氯化反应,合成了6-氟-4-氯喹唑啉,然后在微波辐射下与芳香胺反应,合成了6个新的6-氟-4-(N-芳基)胺基喹唑啉类化合物.新化合物经1HNMR,IR及元素分析证明其结构.体外抑瘤试验证明化合物对前列腺癌细胞(PC3)、人胃癌细胞(BGC823)、人乳腺癌细胞(BCap-37)均无抑制活性.经ERK的抗磷酸化活性免疫印迹试验证明化合物对小鼠成纤维细胞(NIH3T3)无抑制活性. Six new 6-fluoro-4-(N-aryl)aminoquinazoline compounds were synthesized, firstly by the cyclization reaction of 2-amino-5-fluorobenzoic acid with formamide and then chlorination to attain 4-chloro-6-fluoroquinazoline, finally the amination with arylamines under microwave irradiation. The structures of the six new compounds were characterized by elemental analyses, IR and ^1H NMR spectra. Bioactivity of the new compounds was tested. The results showed that the six new compounds had weak anticancer activity to PC3, BGC823, BCap-37 and ERK phosphorylation in NIH3T3 cell induced by PDGF.
出处 《有机化学》 SCIE CAS CSCD 北大核心 2006年第9期1275-1278,共4页 Chinese Journal of Organic Chemistry
基金 国家自然科学基金(No.20562003) 2005年贵州省优秀青年科技人才(No.20050515)资助项目.
关键词 喹唑啉 合成 微波辐射 生物活性 qunazoline fluorine synthesis microwave irradiation bloactlvlty
作者简介 E-mail: songbaoan22@yahoo.com; Fax: 0851-3622211.
  • 相关文献

参考文献7

二级参考文献39

  • 1Baselga J, Yano K, Giaccone G, et al. Initial results from a phase trial of ZD 1839(Iressa) as second- and third-line monotherapy for patients with advanced nonsmall cell lung cancer (IDEAL 1 ). Clin Cancer Res,2001,7 (Suppl): 3780S.
  • 2Khuri FR, Rigas JR, Figlin RA, et al.Multi-institutional phase Ⅰ / Ⅱ trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol,2001,19(10) : 2626-2637.
  • 3Hidalgo M, Siu LL, Nemunaitis J, et al.Phase Ⅰ and pharmacologic study of OSI774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol,2001,19(13): 3267-3279.
  • 4Swisher SG, Roth JA, Komaki R, et al. A phase Ⅱ trial of adenoviral mediated p53gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol,2000,19 : 461a.
  • 5Kris MG, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in phase Ⅰ trails of oral ZD 1839 (lressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Canc
  • 6AwadaA, Gil T, De Valeriola D, et al. A Phase Ⅰ , clinical and pharmacokinetic trial of Zarnestra (farnesyl transferase inhibitor, R115777) and docetaxel: A promising combination in patients with solid tumors.Clin Cancer Res,2001,7 (Suppl): 3774S.
  • 7Sharma S, Kemeny N, Kelsen DP, et al.A phase Ⅱ trial of farnesyl protein transferase inhibitor SCH 66336, given by twicedaily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol,2002,1
  • 8Dickler MN, Ragupathi G, Liu NX, et al.Immunogenicity of a fucosyl-GMl-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res,1999,5(10): 2773-2779.
  • 9Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res,2000,6(12): 4607-4609.
  • 10Achiwa H, Yatabe Y, Hida T, et al.Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res,1999,5(5) : 1001-1005.

共引文献50

同被引文献101

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部